Zum Hauptinhalt springen

Significance and Role of Pattern Recognition Receptors in Malignancy.

Żeromski, J ; Kaczmarek, M ; et al.
In: Archivum immunologiae et therapiae experimentalis, Jg. 67 (2019-06-01), Heft 3, S. 133-141
academicJournal

Titel:
Significance and Role of Pattern Recognition Receptors in Malignancy.
Autor/in / Beteiligte Person: Żeromski, J ; Kaczmarek, M ; Boruczkowski, M ; Kierepa, A ; Kowala-Piaskowska, A ; Mozer-Lisewska, I
Zeitschrift: Archivum immunologiae et therapiae experimentalis, Jg. 67 (2019-06-01), Heft 3, S. 133-141
Veröffentlichung: 2024- : Warsaw, Poland : Sciendo ; <i>Original Publication</i>: Warszawa, Panstwowy Zakład Wydawn. Lekarskich., 2019
Medientyp: academicJournal
ISSN: 1661-4917 (electronic)
DOI: 10.1007/s00005-019-00540-x
Schlagwort:
  • Adaptive Immunity drug effects
  • Animals
  • Antineoplastic Agents, Immunological therapeutic use
  • DNA immunology
  • DNA metabolism
  • Disease Models, Animal
  • Humans
  • Immunity, Innate drug effects
  • Ligands
  • Lymphocytes, Tumor-Infiltrating drug effects
  • Lymphocytes, Tumor-Infiltrating immunology
  • Lymphocytes, Tumor-Infiltrating metabolism
  • Neoplasms drug therapy
  • Neoplasms pathology
  • RNA immunology
  • RNA metabolism
  • Receptors, Pattern Recognition agonists
  • Receptors, Pattern Recognition immunology
  • Antineoplastic Agents, Immunological pharmacology
  • Immunotherapy methods
  • Neoplasms immunology
  • Receptors, Pattern Recognition metabolism
Sonstiges:
  • Nachgewiesen in: MEDLINE
  • Sprachen: English
  • Publication Type: Journal Article; Review
  • Language: English
  • [Arch Immunol Ther Exp (Warsz)] 2019 Jun; Vol. 67 (3), pp. 133-141. <i>Date of Electronic Publication: </i>2019 Apr 11.
  • MeSH Terms: Antineoplastic Agents, Immunological / *pharmacology ; Immunotherapy / *methods ; Neoplasms / *immunology ; Receptors, Pattern Recognition / *metabolism ; Adaptive Immunity / drug effects ; Animals ; Antineoplastic Agents, Immunological / therapeutic use ; DNA / immunology ; DNA / metabolism ; Disease Models, Animal ; Humans ; Immunity, Innate / drug effects ; Ligands ; Lymphocytes, Tumor-Infiltrating / drug effects ; Lymphocytes, Tumor-Infiltrating / immunology ; Lymphocytes, Tumor-Infiltrating / metabolism ; Neoplasms / drug therapy ; Neoplasms / pathology ; RNA / immunology ; RNA / metabolism ; Receptors, Pattern Recognition / agonists ; Receptors, Pattern Recognition / immunology
  • Comments: Erratum in: Arch Immunol Ther Exp (Warsz). 2019 Aug 31;:. (PMID: 31473789)
  • References: Nat Rev Immunol. 2004 Jul;4(7):499-511. (PMID: 15229469) ; Cancer Res. 2005 Jun 15;65(12):5009-14. (PMID: 15958541) ; South Med J. 2005 Sep;98(9):914-20. (PMID: 16217984) ; J Immunol. 2006 Apr 15;176(8):4894-901. (PMID: 16585585) ; Br J Cancer. 2006 Aug 7;95(3):247-52. (PMID: 16892041) ; Eur Arch Otorhinolaryngol. 2007 May;264(5):525-30. (PMID: 17165086) ; J Clin Invest. 2007 May;117(5):1184-94. (PMID: 17476348) ; Gastroenterology. 2007 Dec;133(6):1869-81. (PMID: 18054559) ; Clin Cancer Res. 2008 Feb 1;14(3):856-64. (PMID: 18245549) ; Adv Drug Deliv Rev. 2008 Apr 29;60(7):786-94. (PMID: 18280610) ; J Interferon Cytokine Res. 2008 Apr;28(4):253-63. (PMID: 18439103) ; Cancer Microenviron. 2008 Dec;1(1):37-42. (PMID: 19308683) ; Cancer Res. 2009 Apr 1;69(7):3105-13. (PMID: 19318560) ; Lancet. 2009 Jul 25;374(9686):301-14. (PMID: 19586656) ; Trends Immunol. 2010 Oct;31(10):391-7. (PMID: 20832362) ; Folia Histochem Cytobiol. 2010 Dec;48(4):624-31. (PMID: 21478107) ; Clin Dev Immunol. 2012;2012:785825. (PMID: 22013487) ; Oncol Rep. 2012 Feb;27(2):396-402. (PMID: 22075935) ; Sci Transl Med. 2012 Feb 8;4(120):120ra16. (PMID: 22323829) ; Am J Hematol. 2012 Oct;87(10):953-6. (PMID: 22718533) ; Eur J Immunol. 2013 Jan;43(1):147-58. (PMID: 22996354) ; Clin Cancer Res. 2012 Dec 15;18(24):6668-78. (PMID: 23048078) ; Proc Natl Acad Sci U S A. 2013 May 14;110(20):E1857-66. (PMID: 23630282) ; Immunobiology. 2013 Nov;218(11):1322-35. (PMID: 23896194) ; J Immunol. 2013 Nov 1;191(9):4473-4. (PMID: 24141853) ; J Immunol. 2014 Feb 1;192(3):1171-83. (PMID: 24391214) ; Leukemia. 2014 Aug;28(8):1716-24. (PMID: 24476765) ; J Virol. 2014 Aug;88(16):9245-59. (PMID: 24899179) ; Front Immunol. 2014 Jul 22;5:336. (PMID: 25101079) ; Gynecol Oncol. 2014 Nov;135(2):359-63. (PMID: 25135000) ; Cancer Res. 2014 Nov 1;74(21):6224-35. (PMID: 25205107) ; Annu Rev Immunol. 2015;33:445-74. (PMID: 25622193) ; Oncogene. 2015 Oct 8;34(41):5302-8. (PMID: 25639870) ; Sci Rep. 2015 May 21;5:10501. (PMID: 25994622) ; ACS Cent Sci. 2015 Nov 25;1(8):439-448. (PMID: 26640818) ; Cell Rep. 2016 Jan 12;14(2):282-97. (PMID: 26748708) ; PLoS One. 2016 Jan 19;11(1):e0146835. (PMID: 26784926) ; PLoS One. 2016 Feb 29;11(2):e0148764. (PMID: 26928328) ; Cancer Res. 2016 Apr 15;76(8):2076-81. (PMID: 26964621) ; Cell Rep. 2016 Mar 22;14(11):2562-75. (PMID: 26971998) ; Life Sci. 2016 Jun 15;155:133-9. (PMID: 27177773) ; Immunity. 2016 May 17;44(5):1177-89. (PMID: 27178469) ; J Immunol. 2016 Jun 15;196(12):5121-9. (PMID: 27183588) ; Cancer Res. 2016 Jun 1;76(11):3122-6. (PMID: 27197163) ; Immunology. 2016 Aug;148(4):315-25. (PMID: 27213842) ; Medicine (Baltimore). 2016 Jun;95(25):e3951. (PMID: 27336891) ; Anticancer Res. 2016 Jul;36(7):3383-94. (PMID: 27354597) ; Genet Mol Res. 2016 Jul 14;15(2):. (PMID: 27420991) ; Exp Cell Res. 2016 Oct 1;347(2):274-82. (PMID: 27426724) ; Trends Immunol. 2016 Sep;37(9):569-570. (PMID: 27452288) ; Tumour Biol. 2016 Oct;37(10):13279-13286. (PMID: 27460076) ; Cancer Immunol Immunother. 2016 Oct;65(10):1201-12. (PMID: 27522582) ; Cancer Res. 2016 Nov 15;76(22):6747-6759. (PMID: 27680683) ; PLoS One. 2016 Oct 7;11(10):e0164401. (PMID: 27716850) ; Mol Carcinog. 2017 Apr;56(4):1214-1226. (PMID: 27805282) ; Int J Mol Sci. 2016 Dec 08;17(12):. (PMID: 27941651) ; Oncotarget. 2017 Feb 14;8(7):11708-11718. (PMID: 28052019) ; Trends Immunol. 2017 Mar;38(3):194-205. (PMID: 28073693) ; Cell Immunol. 2017 Mar;313:52-58. (PMID: 28089340) ; Sci Rep. 2017 Feb 08;7:39858. (PMID: 28176788) ; Nucleic Acids Res. 2017 Feb 17;45(3):1442-1454. (PMID: 28180316) ; Virchows Arch. 2017 Apr;470(4):401-410. (PMID: 28191612) ; Int J Mol Sci. 2017 Feb 14;18(2):. (PMID: 28216575) ; Cell Mol Life Sci. 2017 Jul;74(13):2395-2411. (PMID: 28224203) ; Curr Med Chem. 2017;24(19):2011-2032. (PMID: 28322156) ; Tumour Biol. 2017 Mar;39(3):1010428317694312. (PMID: 28347236) ; Oncol Rep. 2017 May;37(5):3137-3145. (PMID: 28350104) ; Int J Cancer. 2017 Aug 1;141(3):561-571. (PMID: 28401532) ; Life Sci. 2017 Jun 15;179:80-87. (PMID: 28472619) ; Oncogene. 2017 Sep 7;36(36):5134-5144. (PMID: 28481875) ; J Leukoc Biol. 2017 Aug;102(2):423-436. (PMID: 28533357) ; Int J Mol Epidemiol Genet. 2017 Apr 15;8(2):8-18. (PMID: 28533893) ; Cell Physiol Biochem. 2017;42(2):469-479. (PMID: 28578348) ; Tumour Biol. 2017 Jun;39(6):1010428317710586. (PMID: 28653898) ; J Biol Chem. 2017 Sep 15;292(37):15408-15425. (PMID: 28717003) ; J Virol. 2017 Sep 12;91(19):. (PMID: 28724760) ; Arch Immunol Ther Exp (Warsz). 2018 Apr;66(2):125-132. (PMID: 28748479) ; Trends Immunol. 2018 Jan;39(1):44-54. (PMID: 28830732) ; Cancer Immunol Immunother. 2017 Dec;66(12):1619-1629. (PMID: 28856441) ; Int J Cancer. 2018 Jan 1;142(1):81-91. (PMID: 28875549) ; Transl Res. 2017 Dec;190:51-60. (PMID: 28917654) ; Adv Exp Med Biol. 2017;1024:195-212. (PMID: 28921471) ; Anticancer Res. 2017 Oct;37(10):5515-5519. (PMID: 28982864) ; Immunol Lett. 2018 Jan;193:58-66. (PMID: 29103998) ; Int J Oncol. 2018 Jan;52(1):139-154. (PMID: 29138803) ; Nat Immunol. 2018 Jan;19(1):53-62. (PMID: 29180807) ; PLoS One. 2017 Nov 30;12(11):e0188738. (PMID: 29190690) ; Biochem Biophys Res Commun. 2018 Jan 15;495(3):2227-2234. (PMID: 29269299) ; Front Immunol. 2017 Dec 21;8:1897. (PMID: 29312355) ; Front Immunol. 2018 Jan 05;8:1927. (PMID: 29354132) ; Cancer Sci. 2018 Apr;109(4):956-965. (PMID: 29465830) ; FASEB J. 2018 Aug;32(8):4132-4144. (PMID: 29509510) ; Oncol Lett. 2018 Apr;15(4):4697-4705. (PMID: 29541243) ; Front Immunol. 2018 Apr 09;9:711. (PMID: 29686682) ; Proc Natl Acad Sci U S A. 2018 Jul 17;115(29):E6836-E6844. (PMID: 29967183)
  • Grant Information: 2016/23/B/NZ6/013497 National Science Center (NCN) Poland
  • Contributed Indexing: Keywords: Agonists; Cancer cells; Nucleic-acid sensing; PRRs; RLRs; TLRs; cGAS-STING pathway
  • Substance Nomenclature: 0 (Antineoplastic Agents, Immunological) ; 0 (Ligands) ; 0 (Receptors, Pattern Recognition) ; 63231-63-0 (RNA) ; 9007-49-2 (DNA)
  • Entry Date(s): Date Created: 20190413 Date Completed: 20190911 Latest Revision: 20200225
  • Update Code: 20240513
  • PubMed Central ID: PMC6509067

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

oder
oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

oder
oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -